Radiolabelled Tracking Study

Radiolabelled tracking study employs radioactive markers quantitating drug tissue distribution and excretion. Carbon-14 or hydrogen-3 labelling tracks organic drugs. Positron emission tomography enables imaging. Whole-body autoradiography visualises distribution. Excretion route characterisation informs elimination understanding.

Regulatory submissions include radiolabelled study data. Metabolism pathway identification guides drug design. Tissue accumulation assessment informs safety. Post-approval monitoring confirms predicted distribution. Emerging imaging technologies reduce radiation exposure.